The Menarini Group adheres to the principles set forth in the “JOINT POSITION ON THE DISCLOSURE OF CLINICAL TRIAL INFORMATION VIA CLINICAL TRIAL REGISTRIES AND DATABASES”, which represents the position agreed upon by the international pharmaceutical associations EFPIA (European Federation of Pharmaceutical Industries and Associations), IFPMA (International Federation of Pharmaceutical Manufacturers and Associations), JPMA (Japanese Pharmaceutical Manufacturers Association) and PhRMA (Pharmaceutical Research and Manufacturers of America), with the aim of making information on Clinical Trials readily and easily accessible, in the context of transparency in Clinical Research by the Industry, with the commitment to providing patients and health personnel with all the relevant information on newly developed products.
We are committed to publish in the scientific literature results from all Menarini Group-sponsored interventional trials (excluded ones in healthy subjects, i.e. those studies without any therapeutic objective), irrespective whether the results are positive or negative. This commitment also applies to investigational medicines whose development programs have been discontinued.
The Menarini Group has several alliances with other pharmaceutical companies worldwide. As a consequence, Menarini might not be the formal sponsor of all clinical studies for a given product in its portfolio, and the results of such studies may not be included on our database. For any information about studies sponsored by our alliance companies, please refer to public registries such as ClinicalTrials.gov or EU Clinical Trials Register.